1,270
Views
3
CrossRef citations to date
0
Altmetric
Review

Tocilizumab for the treatment of non‐critical COVID‐19 pneumonia: an overview of the rationale and clinical evidence to date

&
Pages 1279-1287 | Received 16 Apr 2021, Accepted 25 Jun 2021, Published online: 26 Jul 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Masashi Narazaki & Tadamitsu Kishimoto. (2022) Current status and prospects of IL-6–targeting therapy. Expert Review of Clinical Pharmacology 15:5, pages 575-592.
Read now

Articles from other publishers (2)

Engy Elekhnawy, Walaa A. Negm, Suzy A. El-Sherbeni & Ahmed Zayed. (2022) Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols. Inflammopharmacology 30:6, pages 1935-1954.
Crossref
Manuel Rubio‐Rivas, Carlos G. Forero, José María Mora‐Luján, Abelardo Montero, Francesc Formiga, Narcís A. Homs, Joan Albà‐Albalate, Laura Sánchez, Jordi Rello & Xavier Corbella. (2021) Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: A systematic review and meta‐analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41:11, pages 884-906.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.